Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.
Akero Therapeutics Marching On & Delivering Promising Results • Prudent Biotech
Akero Therapeutics is making strong progress in developing a treatment for NASH, an area of high unmet medical need. The company’s lead product candidate has
June 13, 2023